UC Berkeley UC Berkeley Previously Published Works

Title

TOR complex 2-regulated protein kinase Ypk1 controls sterol distribution by inhibiting StARkin domain-containing proteins located at plasma membrane-endoplasmic reticulum contact sites

Permalink https://escholarship.org/uc/item/43m0d7dk

Journal Molecular Biology of the Cell, 29(17)

ISSN

1059-1524

Authors

Roelants, Françoise M Chauhan, Neha Muir, Alexander <u>et al.</u>

Publication Date

2018-08-15

DOI

10.1091/mbc.e18-04-0229

Peer reviewed

TOR Complex 2-regulated protein kinase Ypk1 controls sterol distribution by inhibiting StARkin domain-containing proteins located at plasma membrane-endoplasmic reticulum contact sites

Françoise M. Roelants¹, Neha Chauhan², Alexander Muir^{1#}, Jameson C. Davis¹, Anant K. Menon², Timothy P. Levine³, and Jeremy Thorner^{1*}

¹Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720-3202, USA

²Department of Biochemistry, Weill Cornell Medical College, New York, NY 10065, USA

³UCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK

Running Title: Ypk1 regulates sterol transporter Ysp2

[#]Current address: Vander Heiden Lab, Department of Biology and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

*To whom correspondence should be addressed:

Professor Jeremy Thorner Division of Biochemistry, Biophysics and Structural Biology Department of Molecular and Cell Biology University of California at Berkeley Room 526, Barker Hall Berkeley, CA 94720-3202, USA Phone: (510) 642-2558 FAX: (510) 642-6420 e-mail: jthorner@berkeley.edu

ABSTRACT

In our proteome-wide screen (Muir *et al.* 2014 *Elife*), Ysp2 (also known as Lam2/Ltc4) was identified as a likely physiologically relevant target of TORC2-dependent protein kinase Ypk1 in the yeast *Saccharomyces cerevisiae*. Ysp2 was subsequently shown to be one of a new family of sterol-binding proteins located at plasma membrane (PM)-endoplasmic reticulum (ER) contact sites (Gatta et al. 2015 *Elife*). Here we document that Ysp2 and its paralog Lam4/Ltc3 are authentic Ypk1 substrates *in vivo* and show using genetic and biochemical criteria that Ypk1-mediated phosphorylation inhibits the ability of these proteins to promote retrograde transport of sterols from the PM to the ER. Furthermore, we provide evidence that a change in PM sterol homeostasis promotes cell survival under membrane-perturbing conditions known to activate TORC2-Ypk1 signaling. These observations define the underlying molecular basis of a new regulatory mechanism for cellular response to plasma membrane stress.

INTRODUCTION

Sterols in the plasma membrane (PM) of eukaryotic cells (VAN MEER *et al.* 2008; HANNICH *et al.* 2011; KLUG AND DAUM 2014) affect its fluidity and permeability, and induce phase separations, including sphingolipid-enriched sterol-containing microdomains that influence the distribution and function of integral membrane proteins (LINGWOOD AND SIMONS 2010; YANG *et al.* 2016). Sterols are synthesized *de novo* in the endoplasmic reticulum (ER) and delivered to the membranes of other organelles, in part, by non-vesicular mechanisms requiring lipid transfer proteins (LTPs) (RAYCHAUDHURI AND PRINZ 2010; CHIAPPARINO *et al.* 2016; DRIN *et al.* 2016; KENTALA *et al.* 2016; DITTMAN AND MENON 2017). One class of sterol-specific LTPs are membrane-anchored Stard transfer (Stard) proteins (TSUJISHITA AND HURLEY 2000; LAVIGNE *et al.* 2010; MAXFIELD *et al.* 2016). Recently, a new family of ER membrane-anchored Stard-like (also called Starkin) domain-containing proteins were discovered that are conserved from yeast (*S. cerevisiae*) to humans and located at ER-PM, ER-mitochondria and ER-vacuole junctions (GATTA *et al.* 2015; MURLEY *et al.* 2015; WONG AND LEVINE 2016). How this novel class of sterol-binding StARkin domain-containing proteins is regulated is poorly understood.

In yeast, the TORC2-activated protein kinase Ypk1 (and its paralog Ypk2) is an essential regulator of PM sphingolipid, glycerolipid and protein homeostasis (ROELANTS *et al.* 2010; ROELANTS *et al.* 2011; LEE *et al.* 2012; MUIR *et al.* 2014; MUIR *et al.* 2015; ALVARO *et al.* 2016; ROELANTS *et al.* 2017). A systematic screen to pinpoint presumptive substrates of Ypk1 identified Ysp2/Lam2/Ltc4 (MUIR *et al.* 2014), one member of the new family of StART-like domain-containing proteins (GATTA *et al.* 2015; MURLEY *et al.* 2015). Contrary to a prior claim that it is a mitochondrial protein (SOKOLOV *et al.* 2006), Ysp2 and its paralog Lam4/Ltc3 are located at ER-PM contact sites and are involved in retrograde transfer of exogenously supplied sterols from the PM to the ER (GATTA *et al.* 2015; MURLEY *et al.* 2015). The StART-like domains isolated from these proteins bind ergosterol and are able to transfer sterols between vesicles *in*

vitro (GATTA *et al.* 2015; MURLEY *et al.* 2015; HORENKAMP *et al.* 2018; JENTSCH *et al.* 2018; TONG *et al.* 2018). Here we confirmed, first, that Ysp2 is an authentic target of Ypk1-mediated phosphorylation. We then investigated whether this modification affects sterol transfer between the PM and the ER. Finally, we examined whether this regulation is important to sustain cell viability under stressful conditions (namely, sphingolipid depletion and high exogenous acetic acid) that are known to activate TORC2-Ypk1 signaling (ROELANTS *et al.* 2011; BERCHTOLD *et al.* 2012; GUERREIRO *et al.* 2016).

RESULTS

Ypk1 phosphorylates Ysp2 and Lam4

Ysp2 has three consensus Ypk1 phosphorylation sites [-R-x-R-x-x-S/T-(Hpo)-, where (Hpo) indicates a preference for a hydrophobic residue] and its paralog Lam4 has two (Fig. 1A), with T518 in Ysp2 located at a similar relative position as S401 in Lam4. We have shown before that one hallmark of authentic Ypk1 substrates is that their over-expression is inhibitory to growth when Ypk1 function is limiting (MUIR et al. 2014). Indeed, in ypk1-as ypk2 cells, which contain an allele of Ypk1 sensitive to inhibition by the adenine analog 3MB-PP1, GAL promoter-driven over-expression of Ysp2 prevented growth more potently in the presence of inhibitor than its absence, but had no effect on otherwise wild-type (WT) cells with or without inhibitor (Fig. 1B). In vitro, purified Ypk1-as phosphorylated both a fragment of Ysp2 containing its T518 site [GST-Ysp2(97-665)] and a fragment of Lam4 containing its S401 site [GST-Lam4(380-666)] in the absence of 3MB-PP1, but not in its presence, and mutation of each of these two residues to Ala confirmed that the observed incorporation was occurring mainly at the expected sites (Fig. 1C). We then focused on examining Ysp2 phosphorylation in vivo because a ysp2 single mutant exhibits a readily detectable defect in retrograde transport of exogenously supplied sterol compared to WT cells, whereas a *lam4*∆ single mutant does not (GATTA et al. 2015). We analyzed the migration pattern of a FLAG-tagged derivative of a C-terminal fragment of Ysp2 [Ysp2(499-1438)] containing two (T518 and T1237) of its three Ypk1 sites using phosphate affinity (Phos-tag[™]) gel electrophoresis (KINOSHITA et al. 2015). Treatment with the sphingolipid biosynthesis inhibitor myriocin, a stress that markedly stimulates TORC2-mediated activation of Ypk1 (ROELANTS et al. 2011; BERCHTOLD et al. 2012), greatly increased the slower mobility (more highly phosphorylated) species concomitantly reduced the fastest and (hypophosphorylated) species, and this myriocin-evoked mobility shift was largely eliminated by mutation of the two Ypk1 sites to Ala (Fig. 2A), by phosphatase treatment (Fig. 2B), or in ypk1as ypk2^Δ cells treated with 3MB-PP1 (Fig. 2C). Thus, Ysp2 is phosphorylated at its Ypk1 sites

in vivo and in a manner reflecting the state of Ypk1 activation.

Ypk1 phosphorylation inhibits Ysp2 function

Comparison of WT Ysp2 with a mutant (Ysp2^{AAA}) lacking all three of the Ypk1 consensus phosphoacceptor sites demonstrated that neither the steady-state level (Fig. 3A) nor the localization (Fig. 3B) of Ysp2 is affected by the lack of Ypk1-mediated phosphorylation. As a first means to examine whether Ypk1 phosphorylation affects Ysp2 function, we took advantage of the fact that killing by the antibiotic amphotericin B (AmB) results from its specific interaction with ergosterol in the PM of fungal cells, disrupting the permeability barrier (KAMIŃSKI 2014). Cells lacking Ysp2 are more sensitive to AmB than WT cells (GATTA et al. 2015), indicating an increase in the pool of ergosterol that is accessible to AmB. Indeed, at the concentration of AmB we used, $ysp2\Delta$ cells carrying vector alone were unable to grow, whereas expression of WT Ysp2 from the same vector exhibited detectable growth (Fig. 4A). Strikingly, expression of either Ysp2^{T518A} or Ysp2^{AAA} from the same vector conferred a level of AmB resistance reproducibly higher than that of WT Ysp2 and markedly greater than $ysp2\Delta$ cells (Fig. 4A), indicating that cells expressing Ysp2^{T518A} and Ysp2^{AAA} have even less accessible ergosterol in their PM than in WT cells. This difference is due to a modification in the distribution of ergosterol rather than in the level of cellular ergosterol as Ysp2^{AAA} and WT Ysp2 cells contain the same amount of total ergosterol (Fig. 4B). The change in PM ergosterol homeostasis was confirmed by showing that cells expressing Ysp2^{AAA} are more resistant than cells expressing WT Ysp2 to nystatin, another pore-forming polyene antifungal which functions, in part, by interacting with ergosterol in membranes (DOS SANTOS et al. 2017) (Fig. 4C). Therefore, the role of Ypk1 phosphorylation is to negatively regulate Ysp2 function. Examination of other single mutants (Ysp2^{S44A} and Ysp2^{T1237A}) indicated that the primary inhibitory site is T518 (Fig. 4A). We also tested cells expressing Ysp2^{T518E} and Ysp2^{EEE} mutants to determine whether they might resemble permanently phosphorylated Yps2 and thus be more sensitive to AmB than cells expressing WT Yps2, but this was not the case (Supplemental Fig. 1A and 1B), indicating that, in this protein,

an acidic residue(s) does not mimic its authentic phosphorylation.

Given the importance of T518 in Ysp2 for its negative regulation by Ypk1, and the similar location of S401 in Lam4, we also tested the AmB sensitivity of WT Lam4 and a Lam4^{S401A} mutant. At the concentration of AmB used, *ysp2∆ lam4∆* double mutant cells carrying vector alone were unable to grow [cells lacking both Lam4 and Ysp2 are more sensitive to AmB than those lacking Ysp2 alone (Supplemental Fig. 2)], whereas expression of WT Ysp2 from the same vector restored readily detectable growth and expression of Ysp2^{T518A} conferred a markedly greater level of AmB resistance, as expected (Fig. 4D). Expression from the same vector of WT Lam4 restored only a very modest degree of growth, but, revealingly, expression of Lam4^{S410A} reproducibly conferred a greater degree of AmB resistance. The observed phenotype of Lam4^{S401A} (Fig. 4D) indicates that phosphorylation by Ypk1 also negatively regulates Lam4.

Ysp2 promotes the retrograde transport of exogenously supplied sterols from the PM to the ER, detected by measuring conversion of sterols to steryl esters by the ER-localized acyltransferases Are1 and Are2 (Fig. 5A) (GATTA *et al.* 2015). Therefore, as a second and independent way to assess the functional consequences of Ypk1 phosphorylation on Ysp2, we analyzed the rate of uptake and esterification of two different reporter sterols, [³H]cholesterol and fluorescent dehydroergosterol (DHE), using the methods described previously (GEORGIEV *et al.* 2011; GATTA *et al.* 2015) (Fig. 5A). Both cholesterol esters and DHE esters were accumulated faster (by ≥30% and ≥45%, respectively) in cells expressing Ysp2^{AAA} than cells expressing WT Ysp2 (Fig. 5B and 5C), indicating that Ysp2 is more active when it is not phosphorylated by Ypk1. The increased rate of DHE ester accumulation was not attributable to any difference in the efficiency of initial DHE loading in the PM (Fig. 5D) nor to any difference in activity of the ACAT enzymes Are1 and Are2 in cells expressing Ysp2^{AAA} compared to cells expressing WT Ysp2 (Fig. 5E). Thus, these direct biochemical assays confirmed that Ypk1 phosphorylation negatively regulates the ability of Ysp2 to mediate transport of sterols from the

PM to the ER.

A change in ergosterol homeostasis helps compensate for the PM stress of sphingolipid depletion

Our findings predict that activation of TORC2-Ypk1 signaling in response to the sphingolipid depletion caused by myriocin treatment would increase sensitivity to AmB because Ypk1mediated phosphorylation of both Ysp2 and Lam4 would result in more accessible ergosterol in the PM and, further, that this hypersensitivity should be alleviated in the Ysp2^{AAA} mutant (Fig. 6A). To focus on Ysp2 because it seems to have the major influence on sterol influx (GATTA *et al.* 2015), we tested these predictions in *lam4*∆ cells. In agreement with our hypothesis, we found, first, that a concentration of AmB that is sublethal to cells expressing WT Ysp2 in the absence of myriocin treatment was able to kill cells treated with a concentration of myriocin that, by itself, was insufficient to compromise cell viability (Fig. 6B). Second, cells expressing WT Ysp2 (Fig. 6B). Thus, when activated by myriocin treatment, Ypk1-mediated phosphorylation of Ysp2 leads to an increase of accessible PM ergosterol, enhancing sensitivity to AmB.

The change in ergosterol homeostasis at the PM appears to be important for counteracting a reduction in sphingolipid content because cells expressing $Ysp2^{AAA}$, which have less accessible ergosterol in the PM and are more resistant to AmB than cells expressing WT Ysp2 (Fig. 6C) are, conversely, more sensitive to myriocin than WT cells (Fig. 6D). Consistent with this view, *ysp2* Δ cells, which are very sensitive to killing by AmB (Fig. 6C), are more resistant to myriocin than WT cells (Fig. 6D). Collectively, these results indicate that, upon sphingolipid limitation, activated Ypk1 phosphorylates and impedes Ysp2-mediated ergosterol transport, resulting in enhanced survival under this stressful condition (Fig. 6A and 6D).

As a second and independent way to determine whether activation of TORC2-Ypk1 signaling increases sensitivity to AmB because Ypk1-mediated phosphorylation inhibits Ysp2 and Lam4, cells were grown in medium containing acetic acid, another condition that has been

shown to activate the TORC2-Ypk1 pathway (GUERREIRO *et al.* 2016). Again, in agreement with our hypothesis, a concentration of AmB that is sublethal to cells expressing WT Ysp2 in the absence of acetic acid treatment was able to kill cells treated with a concentration of acetic acid that, by itself, was insufficient to compromise cell viability (Fig. 6E) and cells expressing Ysp2^{AAA} were more resistant to AmB in the presence of acetic acid than cells expressing WT Ysp2 (Fig. 6E). Interestingly, control of ergosterol in the PM appears to contribute to acetic acid toxicity, as cells expressing Ysp2^{AAA}, which have less accessible ergosterol in the PM, are more resistant to acetic acid than cells expressing WT Ysp2, whereas $ysp2\Delta$ cells are much more sensitive than WT cells (Fig. 6F).

DISCUSSION

As documented here, a reduction in sphingolipid levels sensitizes yeast cells to the action of AmB (Fig. 6B). Our findings are in agreement with a study which showed that perturbing sphingolipid production [by null mutations in genes encoding enzymes (Elo2/Fen1 and Elo3/Sur4) involved in synthesis of the very-long-chain fatty acid (C26) that is normally incorporated into yeast ceramides] caused both *S. cerevisiae* and *C. albicans* to be 2- to 5-times more sensitive to AmB than control cells (SHARMA *et al.* 2014). As described here, we found that this effect is due, in significant part, to TORC2-activated Ypk1-mediated phosphorylation and inhibition of Ysp2, thereby leaving more accessible ergosterol in the PM.

Other mechanisms likely also contribute to explaining how a reduction in sphingolipids enhances AmB sensitivity. It has been proposed, for example, that sequestration of ergosterol in sphingolipid-enriched microdomains shields it from AmB (LI AND PRINZ 2004) and from filipin, another, sterol-binding polyene macrolide antibiotic (JIN *et al.* 2008). An "unshielding" model might explain why $ypk1\Delta$ cells are more sensitive to AmB than WT cells (BARI *et al.* 2015). First, $ypk1\Delta$ cells have dysregulated transbilayer lipid asymmetry (ROELANTS 2010). Second, overall sphingolipid levels are lower in $ypk1\Delta$ mutants than in control cells (DA SILVEIRA DOS SANTOS *et al.* 2014) because Ypk1 action stimulates sphingolipid biosynthesis both at its first committed step (ROELANTS *et al.* 2011) and at the level of ceramide synthase (MUIR *et al.* 2014).

Our studies have uncovered a TORC2- and Ypk1-dependent mechanism by which sphingolipid levels regulate PM sterol. Could the opposite be true too? Yeast strains lacking Ypk1 are sensitive to fluconazole, an inhibitor of ergosterol biosynthesis (GUPTA *et al.* 2003; HILLENMEYER *et al.* 2008), and synthesis of certain sphingolipids is upregulated upon sterol depletion in Drosophila (CARVALHO *et al.* 2010). However, in marked contrast to its activation upon sphingolipid depletion (ROELANTS *et al.* 2011; BERCHTOLD *et al.* 2012), TORC2 was not activated when sterol synthesis was blocked by treatment with lovastatin (Supplemental Fig. 3). Lovastatin, a potent inhibitor of HMG-CoA reductase, a key enzyme in the mevalonate pathway,

blocks isoprenoid and sterol synthesis in yeast (BASSON *et al.* 1986; HAMPTON AND RINE 1994; KURANDA *et al.* 2010). Thus, TORC2 does not serve as a "sensor" of sterol depletion. However, a recent study reported a modest elevation in TORC2-Ypk1 activity in $ysp2\Delta$ *lam4* Δ cells, suggesting that an increase in PM ergosterol availability somehow enhances TORC2 function (MURLEY *et al.* 2017). On the basis of a proteome-wide lipidomics screen, it was reported that Ypk1 binds ergosterol and, further, that ergosterol is required for Ypk1 activity (LI *et al.* 2010), and thus that Ypk1 itself might serve as a sterol sensor. However, subsequent work documented that ergosterol is not required for either basal or myriocin-induced Ypk1 function (ROELANTS *et al.* 2011). Moreover, if ergosterol were an essential Ypk1 activator, lack of ergosterol would decrease Ypk1 activity, with a concomitant drop in sphingolipids, which would be deleterious to PM integrity.

Important questions remain about how Ysp2 participates in transfer of sterol from the PM to the ER and how its phosphorylation by Ypk1 impedes that function. Determining if phosphorylation affects the sterol binding and/or transfer properties of Ysp2, its interaction with other lipids in the PM, or its association with other proteins present at ER-PM contact sites, are essential next steps to investigate. In any event, here we have uncovered the mechanism of a previously uncharacterized and physiologically important level of regulation. Moreover, we have documented here that, under conditions that cause PM stress (especially limiting the rate of sphingolipid production), activation of TORC2-Ypk1 signaling and the ensuing inhibition of Ysp2 allows cells to compensate by apparently retarding removal of ergosterol from the PM. Given that Ypk1 has already been shown to control sphingolipid synthesis (ROELANTS *et al.* 2011; MUIR *et al.* 2014), glycerolipid synthesis (LEE *et al.* 2012; MUIR *et al.* 2015) and leaflet distribution (ROELANTS *et al.* 2010), as well as the rate of endocytosis of integral plasma membrane proteins (ALVARO *et al.* 2016; ROELANTS *et al.* 2017), our current findings add sterols to the list of PM components under the control of Ypk1 action.

MATERIALS AND METHODS

Strains and growth conditions Yeast strains used in this study (Table 1) were grown routinely at 30°C. Standard rich (YP) and defined minimal (SC) media (SHERMAN *et al.* 1986) containing either 2% glucose (Glc), 2% raffinose and 0.2% sucrose (Raf-Suc), or 2% galactose (Gal) as the carbon source, as indicated, and supplemented with appropriate nutrients to maintain selection for plasmids, were used for yeast cultivation. For gene induction from the *GAL1* promoter, cells were pre-grown to mid-exponential phase in SC+Raf-Suc medium, Gal was added (2% final concentration), and incubation was continued for 3 h. When cells were treated with myriocin (Sigma-Aldrich Co., St. Louis, MO, USA), the cultures were grown to mid-exponential phase, induced with Gal for 1 h, Myr was added at the final concentrations of 1.25 µM and incubation was continued for an additional 2 h. Standard yeast genetic techniques were performed according to (SHERMAN *et al.* 1986).

Plasmids and recombinant DNA methods Plasmids used in this study (Table 2) were constructed using standard procedures (SAMBROOK *et al.* 1989) in *E. coli* strain DH5α. Fidelity of all constructs was verified by nucleotide sequence analysis. All PCR reactions were performed using Phusion[™] DNA polymerase (ThermoFisher Scientific, Inc., Waltham, MA, USA). Site-directed mutagenesis using appropriate mismatch oligonucleotide primers was conducted using the QuickChange[™] method.

Preparation of cell extracts and immunoblotting The cells in samples (1.5 ml) of an exponentially-growing culture ($A_{600 \text{ nm}} = 0.6$) were collected by brief centrifugation, immediately frozen in liquid N₂ and then lysed by resuspension in 150 µl of 1.85 M NaOH, 7.4% β-mercaptoethanol. Protein in the resulting lysate was precipitated by the addition of 150 µl of 50% trichloroacetic acid on ice. After 10 min, the resulting denatured protein was collected by centrifugation, washed twice with acetone, solubilized by resuspension in 80 µl of 0.1 M Tris,

5% SDS and then 20 µl of a 5X stock of SDS-PAGE sample buffer containing urea was added. After heating at 39°C for 5 min, portions (3 µl) of the samples containing FLAG-Ysp2(499-1438) were resolved on a Phos-tag gel [8% acrylamide, 35 µM Phos-tag reagent (Wako Pure Chemical Industries, Ltd., Osaka, Japan)], and samples (10 µl) containing GFP-Ysp2 were resolved by SDS-PAGE (8% acrylamide), transferred to nitrocellulose, incubated with appropriate primary antibodies in Odyssey[™] buffer (Li-Cor Biosciences, Lincoln, NE, USA), washed, incubated with appropriate secondary antibodies conjugated to infrared fluorophores, and visualized using an Odyssey[™] infrared imaging system (Li-Cor Biosciences). Antibodies used in this work were: 1:10,000 mouse anti-FLAG M2 mAb (Sigma-Aldrich Co., St. Louis, MO, USA), 1:1,000 mouse anti-GFP mAb (Roche Diagnostics Inc.); 1:10,000 rabbit polyclonal anti-Pgk1 antibodies (BAUM *et al.* 1978); 1:20,000 rabbit polyclonal anti-Ypk1 phospho-T662 antibodies (NILES *et al.* 2012); and, 1:1,000 mouse anti-HA.11 epitope mAb (BioLegend, Inc., San Diego, CA, USA).

Protein kinase assay Ypk1-as was expressed and purified to homogeneity from *S. cerevisiae* as described previously (MUR *et al.* 2014), incubated at 30°C in protein kinase assay buffer [50 mM Tris-HCI (pH 7.5), 200 mM NaCl, 10 mM MgCl₂, 0.1 mM EDTA] with 100 μM [γ-³²P]ATP (~5 x 10⁵ cpm/nmole) and 0.5 μg of GST-Ysp2(97-665) or GST-Lam4(380-666) (which were prepared by expression in and purification from *E. coli*, as described below) in the presence or absence of 10 μM 3MB-PP1. After 30 min, reactions were terminated by addition of SDS-PAGE sample buffer containing 6% SDS followed by boiling for 5 min. Labeled proteins were resolved by SDS-PAGE and analyzed by autoradiography using a PhosphorImager[™] (Molecular Dynamics Div., Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA).

Purification of GST-Ysp2(97-665) and GST-Lam4(380-666) fusion proteins Freshly transformed BL21(DE3) cells carrying a plasmid expressing the desired GST-fusion protein

were grown at 37°C to A_{600nm} = 0.6 and expression was induced by addition of isopropyl- β -D-thiogalactopyranoside (0.5 mM final concentration). After vigorous aeration for 4 h at room temperature, cells were harvested and the GST-fusion protein was purified by column chromatography on glutathione-agarose beads using standard procedures.

Fluorescence microscopy Subcellular localization of GFP-Ysp2 by fluorescent microscopy was conducted as described previously (GATTA *et al.* 2015).

Yeast growth assays For cells expressing Ysp2 from the *YSP2* promoter, transformants were cultured overnight in SC media containing 2% dextrose. 10-fold serial dilutions of overnight cultures starting from $OD_{600} = 1.0$ were then made in sterile water and spotted onto SCD solid media containing AmB and/or Myr at the indicated concentrations. For cells expressing Ysp2 from the *GAL1* promoter, transformants were cultured overnight in SC media containing 2% raffinose and 0.2% sucrose and the 10-fold serial dilutions were spotted onto SC solid media with 2% galactose (to induce protein expression) or 2% dextrose (no protein expression). These plates also contained 1:1000 DMSO or 1 μ M 3MB-PP1 to inhibit Ypk1-as kinase activity in the *ypk1-as ypk2* strain. Serially spotted cultures were allowed to grow in the dark at 30°C, then scanned on a flatbed scanner.

Sterol import assays DHE and [³H]cholesterol uptake assays were performed as described previously (GEORGIEV *et al.* 2011; GATTA *et al.* 2015).

ACAT (Acyl-CoA:sterol acyltransferase) activity was assayed *in vitro* as decribed in (GEORGIEV *et al.* 2011). ACAT activity was calculated as moles sterol esterified per microgram protein per minute.

Ergosterol level

Cells from samples (5 ml) of exponentially-growing cultures of Ysp2^{WT} (YFR495) and Ysp2^{AAA}

(YFR494-A) cells were collected by centrifugation and resuspended in 900 μ l of methanol/water (2:1) with 1.5 μ l of sterol-containing Internal Standard mix (SPLASH mix, Avanti Polar Lipids, Inc., Alabaster, AL, USA). Chloroform (400 μ l) and acid-washed glass beads (100 μ l) were added and samples were vortexed at 4°C for 10 min. Samples were then centrifuged for 10 min at 4°C at 15,000xg. The organic phase (100 μ l) was collected and dried under N₂. Lipid species in these samples were analyzed by liquid chromatography mass spectrometry, as described in detail in (KECHESOVA et al. 2017). Ergosterol was detected in positive mode as the (M+H-H2O)+ ion at m/z of 379.3367. Ergosterol peak areas were normalized to peak areas of the SPLASH internal standards to account for sample recovery and relative ergosterol content was then calculated.

ACKNOWLEDGMENTS

We thank Jasper Rine (Univ. of California, Berkeley, CA, USA) for the gift of lovastatin, Ted Powers (Univ. of California, Davis, CA, USA) for the gift of plasmids and anti-Ypk1 phospho-T662 antibodies, and Caroline A. Lewis (Metabolite Profiling Core Facility, MIT, Cambridge, MA, USA) for mass spectrometry analysis of total cellular ergosterol content. This research was supported by the Qatar National Research Fund Grant NPRP7-082-1-014 (to AKM), by UK Biotechnology and Biological Sciences Research Council (BBSRC) Grant #BB/P003818 (to TP), and by NIH R01 Research Grant GM21841 (to JT).

REFERENCES

- Alvaro, C. G., A. Aindow and J. Thorner, 2016 Differential phosphorylation provides a switch to control how α-arrestin Rod1 down-regulates mating pheromone response in *Saccharomyces cerevisiae*. *Genetics* **203**: 299-317.
- Alvaro, C. G., A. F. O'Donnell, D. C. Prosser, A. A. Augustine, A. Goldman *et al.*, 2014 Specific α-arrestins negatively regulate *Saccharomyces cerevisiae* pheromone response by down-modulating the G-protein coupled receptor Ste2. *Mol. Cell. Biol.* **34**: 2660-2681.
- Bardwell, L., J. G. Cook, J. X. Zhu-Shimoni, D. Voora and J. Thorner, 1998 Differential regulation of transcription: repression by unactivated mitogen-activated protein kinase Kss1 requires the Dig1 and Dig2 proteins. *Proc. Natl. Acad. Sci. USA* **95**: 15400-15405.
- Bari, V. K., S. Sharma, M. Alfatah, A. K. Mondal and K. Ganesan, 2015 Plasma membrane proteolipid-3 protein modulates amphotericin B resistance through sphingolipid biosynthetic pathway. *Sci. Rep.* **5**: 9685.
- Basson, M. E., M. Thorsness and J. Rine, 1986 *Saccharomyces cerevisiae* contains two functional genes encoding 3-hydroxy-3-methylglutaryl-coenzyme A reductase. *Proc. Natl. Acad. Sci. USA* **83**: 5563-5567.
- Baum, P., J. Thorner and L. Honig, 1978 Identification of tubulin from the yeast *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. USA* **75:** 4962-4966.
- Berchtold, D., M. Piccolis, N. Chiaruttini, I. Riezman, H. Riezman *et al.*, 2012 Plasma membrane stress induces relocalization of SIm proteins and activation of TORC2 to promote sphingolipid synthesis. *Nat. Cell Biol.* **14:** 542-547.
- Carvalho, M., D. Schwudke, J. L. Sampaio, W. Palm, I. Riezman *et al.*, 2010 Survival strategies of a sterol auxotroph. *Development* **137**: 3675-3685.
- Chiapparino, A., K. Maeda, D. Turei, J. Saez-Rodriguez and A. C. Gavin, 2016 The orchestra of lipid-transfer proteins at the crossroads between metabolism and signaling. *Prog. Lipid Res.* **61:** 30-39.
- da Silveira Dos Santos, A. X., I. Riezman, M. A. Aguilera-Romero, F. David, M. Piccolis *et al.*, 2014 Systematic lipidomic analysis of yeast protein kinase and phosphatase mutants reveals novel insights into regulation of lipid homeostasis. *Mol. Biol. Cell* 25: 3234-3246.
- Dittman, J. S., and A. K. Menon, 2017 Speed limits for nonvesicular intracellular sterol transport. *Trends Biochem. Sci.* **42:** 90-97.
- Dos Santos, A. G., J. T. Marquês, A. C. Carreira, I. R. Castro, A. S. Viana *et al.*, 2017 The molecular mechanism of Nystatin action is dependent on the membrane biophysical properties and lipid composition. *Phys. Chem. Chem. Phys.* **15**: 30078-30088.
- Drin, G., J. Moser von Filseck and A. Čopič, 2016 New molecular mechanisms of inter-organelle lipid transport. *Biochem. Soc. Trans.* **44:** 486-492.
- Gatta, A. T., L. H. Wong, Y. Y. Sere, D. M. Calderón-Noreña, S. Cockcroft *et al.*, 2015 A new family of StART domain proteins at membrane contact sites has a role in ER-PM sterol transport. *Elife* **4**: e07235.
- Georgiev, A. G., D. P. Sullivan, M. C. Kersting, J. S. Dittman, C. T. Beh *et al.*, 2011 Osh proteins regulate membrane sterol organization but are not required for sterol movement between the ER and PM. *Traffic* **12**: 1341-1355.
- Guerreiro, J. F., A. Muir, S. Ramachandran, J. Thorner and I. Sá-Correia, 2016 Sphingolipid

biosynthesis upregulation by TOR complex 2-Ypk1 signaling during yeast adaptive response to acetic acid stress. *Biochem. J.* **473**: 4311-4325.

- Gupta, S. S., V. K. Ton, V. Beaudry, S. Rulli, K. Cunningham *et al.*, 2003 Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis. *J. Biol. Chem.* **278**: 28831-28839.
- Hampton, R. Y., and J. Rine, 1994 Regulated degradation of HMG-CoA reductase, an integral membrane protein of the endoplasmic reticulum, in yeast. *J. Cell Biol.* **125**: 299-312.
- Hannich, J. T., K. Umebayashi and H. Riezman, 2011 Distribution and functions of sterols and sphingolipids. *Cold Spring Harb. Perspect. Biol.* **3:** a004762.
- Hillenmeyer, M. E., E. Fung, J. Wildenhain, S. E. Pierce, S. Hoon *et al.*, 2008 The chemical genomic portrait of yeast: uncovering a phenotype for all genes. *Science* **320**: 362-365.
- Horenkamp, F. A., D. P. Valverde, J. Nunnari and K. M. Reinisch, 2018 Molecular basis for sterol transport by StART-like lipid transfer domains. *EMBO J.* **37:** e98002.
- Jentsch, J. A., I. Kiburu, K. Pandey, M. Timme, T. Ramlall *et al.*, 2018 Structural basis of sterol binding and transport by a yeast StARkin domain. *J. Biol. Chem.* **293:** [Epub ahead of print, 20 Febr 2018].
- Jin, H., J. M. McCaffery and E. Grote, 2008 Ergosterol promotes pheromone signaling and plasma membrane fusion in mating yeast. *J. Cell. Biol.* **180**: 813-826.
- Jones, E. W., 2002 Vacuolar proteases and proteolytic artifacts in *Saccharomyces cerevisiae*. *Mets. Enzymol.* **351:** 127-150.
- Kamiński, D. M., 2014 Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments. *Eur. Biophys. J.* **43**: 453-467.
- Keckesova, Z., J.L. Donaher, J. De Cock, E. Freinkman, S. Lingrell, D.A. Bachovchin, B. Bierie, V. Tischler, A. Noske, M.C. Okondo, F. Reinhardt, P. Thiru, T.R. Golub, J.E. Vance, R.A. Weinberg, 2017 LACTB is a tumor suppressor that modulates lipid metabolism and cell state. *Nature* 543: 681-686.
- Kentala, H., M. Weber-Boyvat and V. M. Olkkonen, 2016 OSBP-related protein family: mediators of lipid transport and signaling at membrane contact sites. *Int. Rev. Cell Mol. Biol.* **321:** 299-340.
- Kinoshita, E., E. Kinoshita-Kikuta and T. Koike, 2015 Advances in Phos-tag-based methodologies for separation and detection of the phosphoproteome. *Biochim. Biophys. Acta* **1854**: 601-608.
- Klug, L., and G. Daum, 2014 Yeast lipid metabolism at a glance. *FEMS Yeast Res.* **14:** 369-388.
- Kuranda, K., J. François and G. Palamarczyk, 2010 The isoprenoid pathway and transcriptional response to its inhibitors in the yeast *Saccharomyces cerevisiae*. *FEMS Yeast Res.* **10**: 14-27.
- Lavigne, P., R. Najmanivich and J. G. Lehoux, 2010 Mammalian StAR-related lipid transfer (START) domains with specificity for cholesterol: structural conservation and mechanism of reversible binding. *Subcell. Biochem.* **51**: 425-437.
- Lee, Y. J., G. R. Jeschke, F. M. Roelants, J. Thorner and B. E. Turk, 2012 Reciprocal phosphorylation of yeast glycerol-3-phosphate dehydrogenases in adaptation to distinct types of stress. *Mol. Cell. Biol.* **32**: 4705-4717.
- Li, X., T. A. Gianoulis, K. Y. Yip, M. Gerstein and M. Snyder, 2010 Extensive in vivo metabolite-

protein interactions revealed by large-scale systematic analyses. Cell 143: 639-650.

- Li, Y., and W. A. Prinz, 2004 ATP-binding cassette (ABC) transporters mediate nonvesicular, raft-modulated sterol movement from the plasma membrane to the endoplasmic reticulum. *J. Biol. Chem.* **279:** 45226-45234.
- Lingwood, D., and K. Simons, 2010 Lipid rafts as a membrane-organizing principle. *Science* **327:** 46-50.
- Maxfield, F. R., D. B. laea and N. H. Pipalia, 2016 Role of STARD4 and NPC1 in intracellular sterol transport. *Biochem. Cell Biol.* **94:** 499-506.
- Muir, A., S. Ramachandran, F. M. Roelants, G. Timmons and J. Thorner, 2014 TORC2dependent protein kinase Ypk1 phosphorylates ceramide synthase to stimulate synthesis of complex sphingolipids. *Elife* **3**: e03779.
- Muir, A., F. M. Roelants, G. Timmons, K. L. Leskoske and J. Thorner, 2015 Down-regulation of TORC2-Ypk1 signaling promotes MAPK-independent survival under hyperosmotic stress. *Elife* 4: e09336.
- Murley, A., R. D. Sarsam, A. Toulmay, J. Yamada, W. A. Prinz *et al.*, 2015 Ltc1 is an ERlocalized sterol transporter and a component of ER-mitochondria and ER-vacuole contacts. *J. Cell Biol.* **209**: 539-548.
- Murley, A., J. Yamada, B. J. Niles, A. Toulmay, W. A. Prinz *et al.*, 2017 Sterol transporters at membrane contact sites regulate TORC1 and TORC2 signaling. *J. Cell Biol.* **216**: 2679-2689.
- Niles, B. J., H. Mogri, A. Hill, A. Vlahakis and T. Powers, 2012 Plasma membrane recruitment and activation of the AGC kinase Ypk1 is mediated by target of rapamycin complex 2 (TORC2) and its effector proteins Slm1 and Slm2. *Proc. Natl. Acad. Sci. USA* **109**: 1536-1541.
- Raychaudhuri, S., and W. A. Prinz, 2010 The diverse functions of oxysterol-binding proteins. *Annu. Rev. Cell Dev. Biol.* **26:** 157-177.
- Rispal, D., S. Eltschinger, M. Stahl, S. Vaga, B. Bodenmiller, Y. Abraham, I. Filipuzzi, N.R. Movva, R. Aebersold, S.B. Helliwell, and R. Loewith, 2015 Target of Rapamycin Complex 2 regulates actin polarization and endocytosis via multiple pathways. *J. Biol. Chem.* **290**: 14963-14978.
- Roelants, F. M., A. G. Baltz, A. E. Trott, S. Fereres and J. Thorner, 2010 A protein kinase network regulates the function of aminophospholipid flippases. *Proc. Natl. Acad. Sci. USA* **107**: 34-39.
- Roelants, F. M., D. K. Breslow, A. Muir, J. S. Weissman and J. Thorner, 2011 Protein kinase Ypk1 phosphorylates regulatory proteins Orm1 and Orm2 to control sphingolipid homeostasis in *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. USA* **108**: 19222-19227.
- Roelants, F. M., K. L. Leskoske, R. T. Pedersen, A. Muir, J. M. Liu *et al.*, 2017 TOR complex 2regulated protein kinase Fpk1 stimulates endocytosis via inhibition of Ark1/Prk1-related protein kinase Akl1 in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **37**: e00627-16.
- Sambrook, J., E. F. Fritsh and T. Maniatis, 1989 Molecular Cloning: A Laboratory Manual, pp. Cold Spring Harbor Lab Press, Cold Spring Harbor, NY.
- Sharma, S., M. Alfatah, V. K. Bari, Y. Rawal, S. Paul *et al.*, 2014 Sphingolipid biosynthetic pathway genes *FEN1* and *SUR4* modulate amphotericin B resistance. *Antimicrob.*

Agents Chemother. 58: 2409-2414.

- Sherman, F., G. R. Fink and J. B. Hicks, 1986 Laboratory Course Manuel for Methods in Yeast Genetics, pp. Cold Spring Harbor Lab Press, Cold Spring Harbor, NY.
- Sikorski, R. S., and P. Hieter, 1989 A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics* **122**: 19-27.
- Sokolov, S., D. Knorre, E. Smirnova, O. Markova, A. Pozniakovsky *et al.*, 2006 Ysp2 mediates death of yeast induced by amiodarone or intracellular acidification. *Biochim. Biophys. Acta* **1757**: 1366-1370.
- Tong, J., M. K. Manik and Y. J. Im, 2018 Structural basis of sterol recognition and nonvesicular transport by lipid transfer proteins anchored at membrane contact sites. *Proc. Natl. Acad. Sci. USA* **115**: E856-E865.
- Tsujishita, Y., and J. H. Hurley, 2000 Structure and lipid transport mechanism of a StAR-related domain. *Nat. Struct. Biol.* **7:** 408-414.
- van Meer, G., D. R. Voelker and G. W. Feigenson, 2008 Membrane lipids: where they are and how they behave. *Nat. Rev. Mol. Cell Biol.* **9:** 112-124.
- Wong, L. H., and T. P. Levine, 2016 Lipid transfer proteins do their thing anchored at membrane contact sites... but what is their thing? *Biochem. Soc. Trans.* **44:** 517-527.
- Yang, S. T., A. J. Kreutzberger, J. Lee, V. Kiessling and L. K. Tamm, 2016 The role of cholesterol in membrane fusion. *Chem. Phys. Lipids* **199**: 136-143.

Strain	Genotype	Source/reference
BY4741	MATa his3∆1 leu2∆0 met15∆0 ura3∆0	Research Genetics, Inc.
yAM135-A	BY4741 Ypk1(L424A):: <i>URA3 ypk</i> 2∆::KanMX4	(Muir <i>et al.</i> 2014)
YFR484	BY4741 <i>ysp2</i> ∆::hphNT1	This study
YFR513	BY4741 <i>ysp2</i> ∆::hphNT1 <i>lam4</i> ∆::KanMX	This study
YFR495	BY4741 Ysp2::URA3	This study
YFR494	BY4741 Ysp2(S44A T518A T1237A)::URA3	This study
YFR514	BY4741 Ysp2(S44A T518A T1237A)::URA3	This study
	<i>lam4</i> ∆::KanMX	
YFR512	BY4741 GFP-Ysp2::URA3	This study
YFR511	BY4741 GFP-Ysp2(S44A T518A T1237A)::URA3	This study
WPY361 (upc2-1)	MATa upc2-1 ura3-1 his3-11,-15 leu2-3,-112 trp1-1	(LI AND PRINZ 2004)
<i>upc2-1 у</i> sp2∆	WPY361 <i>upc2-1 ysp2</i> ∆	(GATTA <i>et al.</i> 2015)
YFR509	WPY361 upc2-1 Ysp2::URA3	This study
YFR510	WPY361 <i>upc2-1</i> Ysp2(S44A T518A	This study
	T1237A):: <i>URA3</i>	
BY4742	MAT $lpha$ his3 $ m \Delta$ 1 leu2 $ m \Delta$ 0 lys2 $ m \Delta$ 0 ura3 $ m \Delta$ 0	Research Genetics, Inc.
YFR516	BY4742 <i>lam4</i> ∆::KanMX <i>LYS2 met15</i> ∆0	This study
YFR517	BY4742 Lam4(S401A):: <i>URA3 LYS2 met15</i> ∆0	This study
YFR519	BY4742 Ysp2(S44A T518A T1237A)::URA3	This study
	Lam4(S401A):: <i>URA3 LYS2 met15</i> ∆0	
BJ2168	leu2 trp1 ura3-52 prb1-1122 pep4-3 pre1-451 gal2	(JONES 2002)
CGA84	MATa leu2∆1::GEV::NATMX pep4∆::HIS3 prb1∆1.6R ura3-52 trp1-1 lys2-801a leu2∆1 his3∆200 can1 GAL	(Alvaro <i>et al.</i> 2014)

Table 1. S. cerevisiae strains used in this study

Table 2. Plasmids used in this study

Plasmid	Description	Source/reference
pRS416	CEN, URA3, vector	(SIKORSKI AND HIETER 1989)
GFP-Ysp2	pRS416 GFP-Ysp2	(GATTA <i>et al.</i> 2015)
pFR333	pRS416 GFP-Ysp2(S44A)	This study
pFR325	pRS416 GFP-Ysp2(T518A)	This study
pFR340	pRS416 GFP-Ysp2(T1237A)	This study
pFR332	pRS416 GFP-Ysp2(S44A T518A T1237A)	This study
pFR335	pRS416 GFP-Ysp2(S44E)	This study
pFR331	pRS416 GFP-Ysp2(T518E)	This study
pFR341	pRS416 GFP-Ysp2(T1237E)	This study
pFR343	pRS416 GFP-Ysp2(S44E T518E T1237E)	This study
GFP-Lam4	pRS416 GFP-Lam4	(GATTA <i>et al.</i> 2015)
pFR358	pRS416 GFP-Lam4(S401A)	This study
YCpLG	CEN, LEU2, GAL1 _{prom} vector	(Bardwell <i>et al.</i> 1998)
pFR355	YCpLG 3xFLAG-Ysp2(499-1438)	This study
pFR357	YCpLG 3xFLAG-Ysp2(499-1438)(T518A T1237A)	This study
pGEX4T-1	GST tag, bacterial expression vector	GE Healthcare, Inc.
pJD4	pGEX4T-1 Lam4(380-666)	This study
pJD5	pGEX4T-1 Lam4(380-666)(S401A)	This study
pGEX6P-1	GST tag, bacterial expression vector	GE Healthcare, Inc.
pAX228	pGEX6P-1 Ysp2(97-665)	This study
pJD6	pGEX6P-1 Ysp2(97-665)(T518A)	This study
pPL215	pRS416 MET25 _{prom} -Ypk1-3xHA	(NILES <i>et al.</i> 2012)
pPL534	pRS416 MET25 _{prom} -Ypk1(S644A T662A)-3xHA	(NILES <i>et al.</i> 2012)

BG1805	2 μ m, <i>URA3</i> , P _{GAL1} , C-terminal tandem affinity (TAP) tag vector	GE Healthcare, Inc.
pJT4317	BG1805 Ypk1-TAP	GE Healthcare, Inc.



Figure 1. **Ypk1 phosphorylates Ysp2 at T518 and Lam4 at S401**. (A) Diagram of the Ysp2/Lam2/Ltc4 and Lam4/Ltc3 proteins showing the localization of the Ypk1 phospho-acceptor site motifs RxRxxS/T Φ (where Φ is any hydrophobic amino acid) in red. Also shown are the PH-like (GRAM) domain in green and the StART domains 1 and 2 in blue, as well as the predicted transmembrane domain in yellow. (B) Serial 10-fold dilutions of wild-type (BY4741) or *ypk1-as ypk2* Δ (yAM135-A) cells transformed with p*GAL-YSP2* (pAX177) were spotted on plates with dextrose (no protein expression) or galactose (to induce protein expression) in the absence (-) or presence of 1 μ M 3MB-PP1. The plates were scanned after incubation for 3 days at 30°C. (C) GST-Ysp2(97-665) (pAX228), GST-Ysp2(97-665)^{T518A} (pJD6), GST-Lam4(380-666) (pJD4), and GST-Lam4(380-666)^{S401A} (pJD5), were purified from *E. coli* and incubated with [γ -³²P]ATP and *ypk1-as*, purified from *S. cerevisiae*, in the absence or presence of 3MB-PP1. The products were then resolved by SDS-PAGE and analyzed.



Figure 2. **Ysp2 is phosphorylated in a Ypk1-dependent manner** *in vivo*. (A) Wild-type (BY4741) cells expressing either 3xFLAG-Ysp2(499-1438) (pFR355) or 3xFLAG-Ysp2^{AA}(499-1438) (pFR357) from the *GAL1* promoter were grown to mid-exponential phase, induced with galactose for 1 hour and then treated with vehicle (-) or 1.25 μ M myriocin for 2 hours, extracts prepared, resolved on a Phos-tag SDS-PAGE (35 μ M Phos-tag) and analyzed by immunoblotting. (B) Extracts of wild-type (BY4741) cells expressing 3xFLAG-Ysp2(499-1438) (pFR355) were treated with phosphatase, resolved on a Phos-tag SDS-PAGE (35 μ M Phos-tag) and analyzed by immunoblotting. (C) The same cells as in (A) as well as *ypk1-as ypk2* Δ (YAM135-A) cells expressing either 3xFLAG-Ysp2(499-1438) (pFR355) or 3xFLAG-Ysp2^{AA}(499-1438) (pFR357) were grown to mid-exponential phase, induced with galactose for 1 hour and then treated with 10 μ M 3MB-PP1 and vehicle (-) or 1.25 μ M myriocin for 2 hours and analyzed as in (A).

Figure 3



Figure 3. **Phosphorylation at the Ypk1 sites does not affect levels or localization of Ysp2.** (A) Extracts from cultures of *ysp2* Δ (YFR484) cells carrying pRS416 (empty vector) or expressing from the same vector GFP-Ysp2, GFP-Ysp2^{S44A} (pFR333), GFP-Ysp2^{T518A} (pFR325), GFP-Ysp2^{T1237A} (pFR340), or GFP-Ysp2^{AAA} (pFR332) were prepared, resolved by SDS-PAGE and analyzed by immunoblotting. (B) Strains GFP-Ysp2 (YFR512) and GFP-Ysp2^{AAA} (YFR511) were grown to mid-exponential phase and viewed with fluorescence microscopy. The numbers indicate the fluorescence (a.u.) per area of cell in sets of three images (400-500 cells per image).

Figure 4



Figure 4. **Phosphorylation at the Ypk1 sites down-regulates the activity of Ysp2.** (A) Serial 10-fold dilutions of *ysp2* Δ (YFR484) cells carrying pRS416 (empty vector) or expressing from the same vector GFP-Ysp2, GFP-Ysp2^{S44A} (pFR333), GFP-Ysp2^{T518A} (pFR325), GFP-Ysp2^{T1237A} (pFR340), or GFP-Ysp2^{AAA} (pFR332) were spotted on plates lacking (-) or containing AmB (0.16 µM). The plates were scanned after incubation for 2 days at 30°C. (B) Total ergosterol levels of Ysp2^{AAA} (YFR494-A) and Ysp2^{WT} (YFR495) cells was quantified as described in Materials and Methods. Four samples of each strain were counted in triplicate. (C) Serial 10-fold dilutions of WT (BY4741) or otherwise isogenic *lam4* Δ (YFR516), Ysp2^{AAA} *lam4* Δ (YFR514), and *ysp2* Δ *lam4* Δ (YFR513) cells were scanned after incubation for 3 days at 30°C. (D) As in (A) except that *ysp2* Δ *lam4* Δ (YFR513) cells carrying pRS416 (empty vector) or expressing from the same vector GFP-Ysp2, GFP-Ysp2^{T518A} (pFR325), GFP-Lam4, or GFP-Lam4^{S401A} (pFR358) were used and the plates were scanned after incubation for 3 days at 30°C.



Figure 5. **Retrograde transfer of sterols is slower when Ysp2 is phosphorylated by Ypk1**. (A) Depiction of the assay. (B) Retrograde traffic of [³H]cholesterol was determined for strains *upc2-1* Ysp2 (YFR509), *upc2-1* ysp2 Δ and *upc2-1* Ysp2^{AAA} (YFR510) as described in Materials and Methods. Mutation in the Upc2 transcription factor is necessary to allow cholesterol uptake. SEM was calculated from the scores of at least three independent experiments [p<0.035]. (C) Wild-type (YFR495), *ysp2* Δ (YFR484) and Ysp2^{AAA} (YFR494) strains were incubated with DHE under hypoxic conditions to enable the fluorescent sterol to enter the PM (hypoxic incubation overcomes "aerobic sterol exclusion" and is required for DHE loading). After chasing cells under

aerobic conditions, lipids were extracted from the cells at the indicated time points and the percentage of DHE that was converted to DHE ester was determined. SEM was calculated from the scores of at least four independent experiments [p<0.0024]. (D) Loading of DHE in the PM of WT Ysp2 (YFR495) and Ysp2^{AAA} (YFR494) cells was determined as described in Materials and Methods. (E) ACAT (Acyl-CoA:sterol acyltransferase) activity was assayed *in vitro* for WT Ysp2 (YFR495) and Ysp2^{AAA} (YFR494) cells, as decribed in Materials and Methods.

Figure 6





indicated concentration. (E) The same cells as in (B) were grown to stationary phase in SCD at pH 4 then serial 10-fold dilutions were made and spotted on SCD plates lacking (-) or containing 0.3 μ M AmB minus or plus 45 mM acetic acid. The plates were scanned after incubation for 4 days at 30°C. (F) Serial 10-fold dilutions of *lam4* Δ (YFR516), Ysp2^{AAA} *lam4* Δ (YFR514), and *ysp2* Δ *lam4* Δ (YFR513) cells grown as in (E) were spotted on plates lacking (-) or containing acetic acid at the indicated concentrations. The plates were scanned after incubation for 3 days at 30°C.

Supplemental Materials Molecular Biology of the Cell

Roelants et al.

Supplement Figure 1. **Ysp2 E mutants do not mimic phosphorylation** (A) Serial 10-fold dilutions of *ysp2* Δ (YFR484) cells carrying pRS416 (empty vector) or expressing from the same vector GFP-Ysp2, GFP-Ysp2^{S44E} (pFR335), GFP-Ysp2^{T518E} (pFR331), GFP-Ysp2^{T1237E} (pFR341), or GFP-Ysp2^{EEE} (pFR343) were spotted on plates lacking (-) or containing AmB (0.16 μ M). The plates were scanned after incubation for 2 days at 30°C. (B) Extracts from cultures of the same cells were prepared, resolved by SDS-PAGE and analyzed by immunoblotting.

Supplemental Figure 2. Lam4 plays a role in AmB resistance. Serial 10-fold dilutions of WT (BY4741) or otherwise isogenic $ysp2\Delta$ (YFR484), $lam4\Delta$ (YFR516), and $ysp2\Delta$ $lam4\Delta$ (YFR513) cells were spotted on plates lacking (-) or containing AmB at the indicated concentrations.

Supplemental Figure 3. **Sterol limitation does not activate TORC2-Ypk1 signaling**. (A) Serial 10-fold dilutions of Ysp2^{AAA} (YFR494-A and YFR494-B) or wild-type Ysp2 (YFR495-A and YFR495-B), *ysp2* Δ and BY4741 cells were spotted on plates lacking (-) or containing lovastatin at the indicated concentrations. (B) Wild-type (BY4741) cells expressing Ypk1-3xHA (pPL215) or Ypk1^{S644A T662A}-3xHA (pPL534) were grown to mid-exponential phase in selective medium and then treated with either vehicle (methanol), myriocin (1.25 µM) for 2 h, or lovastatin (500 µM) for 5 h prior to harvesting. Whole-cell extracts were prepared, resolved by Phos-tag SDS-PAGE and analyzed by immunoblotting with a 1:20,000 dilution of rabbit polyclonal anti-Ypk1 phospho-T662 antibodies (NILES *et al.* 2012); gift of Ted Powers, Univ. of California, Davis) and a 1:1,000 dilution of mouse monoclonal anti-HA.11 epitope antibody (BioLegend, Inc., San Diego, CA).

Supplemental Figure 1



Supplemental Figure 2



Supplemental Figure 3



В



Blot: α -HA